aspirin has been researched along with Carcinoma, Hepatocellular in 114 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent studies have shown that aspirin consumption may reduce the risk of hepatocellular carcinoma (HCC), but their correlation is still not fully understood." | 9.41 | The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis. ( Chen, R; Lin, Z; Wang, S; Xu, Y; Yang, Z; Zuo, L, 2023) |
| "Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development." | 9.41 | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. ( Chan, KE; Chee, D; Fu, CE; Goh, XL; Huang, DQ; Kim, BK; Lee, SW; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, C; Tan, DJH; Tan, EX; Xiao, J; Yong, JN; Zeng, RW, 2023) |
| "The use of aspirin is a potential protective factor against the development of hepatocellular carcinoma (HCC)." | 9.22 | Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis. ( Dang, S; Liu, C; Shi, J; Wang, M; Wang, W; Wang, Y, 2022) |
| "Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC)." | 9.05 | Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. ( Clark, C; Dang, M; Day, AS; Kontogiannis, V; Rahmani, J; Ryan, PM; Salehisahlabadi, A; Varkaneh, HK; Wang, S; Yu, Y; Zhang, Y, 2020) |
| "Recent analyses of large cohorts suggest that statins or aspirin may reduce the risk of hepatocellular carcinoma (HCC)." | 8.90 | Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence? ( Carrat, F, 2014) |
| "A number of studies have shown that aspirin, as commonly prescribed drug, prevents the development of hepatocellular carcinoma (HCC)." | 8.31 | Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription. ( Feng, JY; Geng, Y; Hou, CY; Wang, GW; Wang, YF; Wei, XF; Yang, G; Yuan, HF; Zhang, HH; Zhang, XD; Zhao, LN; Zhao, M, 2023) |
| "Several studies have demonstrated chemopreventive effects of aspirin against hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB)." | 8.31 | Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. ( Cho, EJ; Chung, JW; Kim, YJ; Lee, CH; Lee, J; Lee, JH; Lee, YB; Moon, H; Yoon, JH; Yu, SJ, 2023) |
| "Statins, metformin, and aspirin have been reported to reduce the incidence of hepatocellular carcinoma (HCC)." | 8.31 | Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. ( Aminizadeh, E; Büchler, MW; Chang, DH; Golriz, M; Khajeh, E; Klotz, R; Longerich, T; Mehrabi, A; Merle, U; Moghadam, AD; Ramouz, A; Springfeld, C, 2023) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 8.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "Aspirin and statins have been suggested to prevent hepatocellular carcinoma (HCC)." | 8.02 | Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. ( Choi, SH; Choi, WM; Han, S; Jo, AJ; Kim, HJ; Ko, MJ; Lim, YS, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 8.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies." | 7.96 | Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. ( Choi, DH; Kim, JH; Kim, TS; Lee, HW; Lee, M; Lee, SH; Lee, W; Park, MS; Park, S; Shin, S, 2020) |
| "Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients)." | 7.96 | Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. ( Aleman, S; Chan, AT; Chung, RT; Duberg, AS; Ludvigsson, JF; Simon, TG, 2020) |
| "Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for its effects on risk of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)." | 7.96 | Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS, 2020) |
| "Aspirin use may have chemo-preventive effect on recurrence of hepatitis B virus-related HCC after curative resection." | 7.96 | Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. ( Chao, Y; Chau, GY; Hou, MC; Huang, YH; Huo, TI; Lee, IC; Lee, MH; Lin, HC; Su, CW; Yeh, YC; Young, SH, 2020) |
| "Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited." | 7.88 | Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. ( Chan, AT; Chong, DQ; Chung, RT; Corey, KE; Fuchs, CS; Giovannucci, EL; Ludvigsson, JF; Ma, Y; Meyerhardt, JA; Simon, TG; Zhang, X, 2018) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 7.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "The effect of aspirin on the risk of hepatocellular carcinoma (HCC) remains unclear." | 7.88 | Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. ( Chang, J; Hwang, IC; Kim, K; Park, SM, 2018) |
| "Aspirin not only reduces the incidence of hepatocellular carcinoma (HCC) but also plays a synergistic role with chemotherapy for HCC treatment." | 7.88 | Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell. ( Fang, W; Huang, Z; Liu, B; Liu, S; Liu, W; Wang, L, 2018) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 7.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| " In this study we want to investigate whether aspirin can improve the antitumor efficiency of IFN-α on hepatocellular carcinoma (HCC) through the activation of STAT1." | 7.79 | Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. ( Chen, ZT; Dong, ZR; Guo, ZY; Li, T; Li, XW; Qu, SF; Tang, ZY; Wang, CH; Zhi, XT, 2013) |
| " This study aimed to determine whether aspirin (ASA) shows synergism with doxorubicin (DOX) in HepG2 human hepatocellular carcinoma cells in vitro and in a HepG2 cell xenograft model in BALB/c nude mice." | 7.78 | Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo. ( Choi, YH; Chung, HY; Copple, BL; Hossain, MA; Jang, JY; Kang, YJ; Kim, DH; Kim, GY; Kim, ND; Moon, JO; Yoon, JH, 2012) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. ( Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ, 2011) |
| " A linear relationship was found for both dosage and duration of aspirin use." | 7.01 | Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis. ( Bentley, R; Feng, L; Gao, J; Jiang, Y; Kim, NH; Li, N; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Q; Zhu, Y, 2023) |
| "Aspirin use has been suggested to reduce cancer risk." | 6.72 | Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. ( Li, X; Liu, L; Yu, Y, 2021) |
| "Hepatocellular carcinoma is one of the most common malignant tumors in the digestive tract, so it is necessary to find effective preventive and therapeutic measures." | 6.66 | [Effect of aspirin on hepatocellular carcinoma and its related mechanism]. ( Liu, YW; Niu, JQ; Xu, HQ; Zhou, Q, 2020) |
| "For aspirin, the RR was 1." | 5.91 | Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials. ( Christensen, DH; Eiset, AH; Jepsen, P; Kraglund, F; Villadsen, GE; West, J, 2023) |
| "doxorubicin on HCC-bearing rats and hepatocellular carcinoma (HepG-2) cells." | 5.91 | Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C. ( El Sadda, RR; Elshahawy, ZR; Saad, EA, 2023) |
| "Aspirin use was identified as factors that significantly impact survival ( P < 0." | 5.91 | Effect of aspirin use on survival in patients with hepatocellular carcinoma. ( Aktan, H; Karaoğullarindan, Ü; Ozdemir, AA, 2023) |
| "Aspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB." | 5.72 | Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. ( Cho, EJ; Chung, JW; Jang, H; Kim, YJ; Lee, J; Lee, JH; Lee, YB; Moon, H; Nam, JY; Yoon, JH; Yu, SJ, 2022) |
| "Aspirin has been found to lower the occurrence rates of some cancers through the inhibition of the cyclooxygenase enzyme." | 5.56 | Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. ( Hsu, CY; Hsu, RJ; Hsu, WL; Huang, SY; Liao, YH; Liu, DW; Su, YC; Wang, TH; Wu, CT, 2020) |
| "Six HCC cell lines and a liver cancer cell line including Huh‑7 were used in assays that evaluated cell proliferation, cell cycle, and apoptosis." | 5.56 | Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. ( Fujita, K; Gong, J; Himoto, T; Iwama, H; Kobara, H; Liu, S; Masaki, T; Morishita, A; Nakahara, M; Nomura, T; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Yoneyama, H, 2020) |
| "Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers." | 5.51 | Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS; Yu, SH, 2019) |
| "Recent studies have shown that aspirin consumption may reduce the risk of hepatocellular carcinoma (HCC), but their correlation is still not fully understood." | 5.41 | The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis. ( Chen, R; Lin, Z; Wang, S; Xu, Y; Yang, Z; Zuo, L, 2023) |
| "Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development." | 5.41 | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. ( Chan, KE; Chee, D; Fu, CE; Goh, XL; Huang, DQ; Kim, BK; Lee, SW; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, C; Tan, DJH; Tan, EX; Xiao, J; Yong, JN; Zeng, RW, 2023) |
| " Combination therapy may produce synergic effects with better tumor inhibition as well as lower dosage or side affects." | 5.31 | [Effects of combination of octreotide and aspirin on proliferation of human hepatocellular carcinoma]. ( Tang, CW; Tang, LP; Wang, CH, 2002) |
| "The use of aspirin is a potential protective factor against the development of hepatocellular carcinoma (HCC)." | 5.22 | Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis. ( Dang, S; Liu, C; Shi, J; Wang, M; Wang, W; Wang, Y, 2022) |
| "Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC)." | 5.05 | Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. ( Clark, C; Dang, M; Day, AS; Kontogiannis, V; Rahmani, J; Ryan, PM; Salehisahlabadi, A; Varkaneh, HK; Wang, S; Yu, Y; Zhang, Y, 2020) |
| "Recent analyses of large cohorts suggest that statins or aspirin may reduce the risk of hepatocellular carcinoma (HCC)." | 4.90 | Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence? ( Carrat, F, 2014) |
| "Several studies have demonstrated chemopreventive effects of aspirin against hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB)." | 4.31 | Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. ( Cho, EJ; Chung, JW; Kim, YJ; Lee, CH; Lee, J; Lee, JH; Lee, YB; Moon, H; Yoon, JH; Yu, SJ, 2023) |
| "Statins, metformin, and aspirin have been reported to reduce the incidence of hepatocellular carcinoma (HCC)." | 4.31 | Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. ( Aminizadeh, E; Büchler, MW; Chang, DH; Golriz, M; Khajeh, E; Klotz, R; Longerich, T; Mehrabi, A; Merle, U; Moghadam, AD; Ramouz, A; Springfeld, C, 2023) |
| "A number of studies have shown that aspirin, as commonly prescribed drug, prevents the development of hepatocellular carcinoma (HCC)." | 4.31 | Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription. ( Feng, JY; Geng, Y; Hou, CY; Wang, GW; Wang, YF; Wei, XF; Yang, G; Yuan, HF; Zhang, HH; Zhang, XD; Zhao, LN; Zhao, M, 2023) |
| "Fibrinogen-like protein 1 (FGL1) has been associated with improved survival in hepatocellular carcinoma (HCC)." | 4.31 | Aspirin and immunotherapy: a Faustian bargain? ( Goethe, EA; Heimberger, AB; Rao, G, 2023) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 4.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 4.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Globally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib." | 4.02 | Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. ( Astara, G; Bernardini, L; Casadei-Gardini, A; Cascinu, S; D'Amico, FE; Dadduzio, V; Fornaro, L; Lai, E; Lonardi, S; Masi, G; Pretta, A; Rimini, M; Rovesti, G; Scartozzi, M; Vivaldi, C; Zagonel, V, 2021) |
| "Aspirin and statins have been suggested to prevent hepatocellular carcinoma (HCC)." | 4.02 | Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. ( Choi, SH; Choi, WM; Han, S; Jo, AJ; Kim, HJ; Ko, MJ; Lim, YS, 2021) |
| "Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for its effects on risk of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)." | 3.96 | Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS, 2020) |
| "Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies." | 3.96 | Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. ( Choi, DH; Kim, JH; Kim, TS; Lee, HW; Lee, M; Lee, SH; Lee, W; Park, MS; Park, S; Shin, S, 2020) |
| "Aspirin use may have chemo-preventive effect on recurrence of hepatitis B virus-related HCC after curative resection." | 3.96 | Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. ( Chao, Y; Chau, GY; Hou, MC; Huang, YH; Huo, TI; Lee, IC; Lee, MH; Lin, HC; Su, CW; Yeh, YC; Young, SH, 2020) |
| "Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients)." | 3.96 | Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. ( Aleman, S; Chan, AT; Chung, RT; Duberg, AS; Ludvigsson, JF; Simon, TG, 2020) |
| "Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation." | 3.88 | Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. ( Tseng, CH, 2018) |
| "Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited." | 3.88 | Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. ( Chan, AT; Chong, DQ; Chung, RT; Corey, KE; Fuchs, CS; Giovannucci, EL; Ludvigsson, JF; Ma, Y; Meyerhardt, JA; Simon, TG; Zhang, X, 2018) |
| "Aspirin not only reduces the incidence of hepatocellular carcinoma (HCC) but also plays a synergistic role with chemotherapy for HCC treatment." | 3.88 | Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell. ( Fang, W; Huang, Z; Liu, B; Liu, S; Liu, W; Wang, L, 2018) |
| "The effect of aspirin on the risk of hepatocellular carcinoma (HCC) remains unclear." | 3.88 | Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. ( Chang, J; Hwang, IC; Kim, K; Park, SM, 2018) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| " Built on these observations, a recent preclinical study took advantage of a previously established hepatitis B virus (HBV) transgenic mouse model of immune-mediated chronic hepatitis that progresses to hepatocellular carcinoma (HCC), to demonstrate that clinically achievable doses of the anti-platelet drugs aspirin and clopidogrel - administered continuously after the onset of liver disease - can prevent hepatocarcinogenesis and greatly improve overall survival." | 3.79 | Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. ( Guidotti, LG; Iannacone, M; Sitia, G, 2013) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 3.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| " In this study we want to investigate whether aspirin can improve the antitumor efficiency of IFN-α on hepatocellular carcinoma (HCC) through the activation of STAT1." | 3.79 | Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. ( Chen, ZT; Dong, ZR; Guo, ZY; Li, T; Li, XW; Qu, SF; Tang, ZY; Wang, CH; Zhi, XT, 2013) |
| " This study aimed to determine whether aspirin (ASA) shows synergism with doxorubicin (DOX) in HepG2 human hepatocellular carcinoma cells in vitro and in a HepG2 cell xenograft model in BALB/c nude mice." | 3.78 | Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo. ( Choi, YH; Chung, HY; Copple, BL; Hossain, MA; Jang, JY; Kang, YJ; Kim, DH; Kim, GY; Kim, ND; Moon, JO; Yoon, JH, 2012) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. ( Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ, 2011) |
| "The frequency of metastases of malignant diethylnitrosamine-induced hepatomas and haemangioendotheliomas of the liver of female Sprague-Dawley rats (29%) was not influenced by application of acetyl-salicylic acid or phenprocoumon." | 3.65 | [Studies on the influence of anticoagulants on metastase formation of autochthonic hepatomas in the rat (author's transl)]. ( Schmähl, D, 1975) |
| " A linear relationship was found for both dosage and duration of aspirin use." | 3.01 | Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis. ( Bentley, R; Feng, L; Gao, J; Jiang, Y; Kim, NH; Li, N; Liu, H; Lowe, S; Ma, S; Qu, G; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Q; Zhu, Y, 2023) |
| "Aspirin use has been suggested to reduce cancer risk." | 2.72 | Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. ( Li, X; Liu, L; Yu, Y, 2021) |
| "Hepatocellular carcinoma is one of the most common malignant tumors in the digestive tract, so it is necessary to find effective preventive and therapeutic measures." | 2.66 | [Effect of aspirin on hepatocellular carcinoma and its related mechanism]. ( Liu, YW; Niu, JQ; Xu, HQ; Zhou, Q, 2020) |
| "For the prevention of oesophageal cancer, antitumour-B and retinamide have provided hopeful results, although it is not clear that these findings can be extrapolated from the study populations in Asia to western countries." | 2.43 | Chemoprevention in gastrointestinal cancers: current status. ( Baron, JA; Grau, MV; Rees, JR, 2006) |
| "For aspirin, the RR was 1." | 1.91 | Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials. ( Christensen, DH; Eiset, AH; Jepsen, P; Kraglund, F; Villadsen, GE; West, J, 2023) |
| "Aspirin use was identified as factors that significantly impact survival ( P < 0." | 1.91 | Effect of aspirin use on survival in patients with hepatocellular carcinoma. ( Aktan, H; Karaoğullarindan, Ü; Ozdemir, AA, 2023) |
| "doxorubicin on HCC-bearing rats and hepatocellular carcinoma (HepG-2) cells." | 1.91 | Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C. ( El Sadda, RR; Elshahawy, ZR; Saad, EA, 2023) |
| "Aspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB." | 1.72 | Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. ( Cho, EJ; Chung, JW; Jang, H; Kim, YJ; Lee, J; Lee, JH; Lee, YB; Moon, H; Nam, JY; Yoon, JH; Yu, SJ, 2022) |
| "Aspirin has been found to lower the occurrence rates of some cancers through the inhibition of the cyclooxygenase enzyme." | 1.56 | Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. ( Hsu, CY; Hsu, RJ; Hsu, WL; Huang, SY; Liao, YH; Liu, DW; Su, YC; Wang, TH; Wu, CT, 2020) |
| "Six HCC cell lines and a liver cancer cell line including Huh‑7 were used in assays that evaluated cell proliferation, cell cycle, and apoptosis." | 1.56 | Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. ( Fujita, K; Gong, J; Himoto, T; Iwama, H; Kobara, H; Liu, S; Masaki, T; Morishita, A; Nakahara, M; Nomura, T; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Yoneyama, H, 2020) |
| "Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers." | 1.51 | Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS; Yu, SH, 2019) |
| "Recurrence of hepatocellular carcinoma (HCC) with unsatisfactory survival is common after surgical resection." | 1.43 | Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. ( Chao, Y; Chen, CC; Chen, TJ; Hu, YW; Huang, YH; Huo, TI; Lee, PC; Lin, HC; Liu, CJ; Su, CW; Wu, JC; Yeh, CM, 2016) |
| "Aspirin has been reported to regulate lipid metabolism." | 1.42 | Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. ( Cai, Y; Duan, W; Feng, Y; He, Z; Hu, T; Li, G; Peng, Y; Tian, Y; Zhang, J, 2015) |
| "Accelerated progression of residual hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (RFA) has been reported more frequently." | 1.42 | Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. ( Ding, J; Duan, B; Jiang, T; Lu, S; Zhang, X, 2015) |
| "Treatment with aspirin and clopidogrel during the chronic phase of the disease diminished the number of intrahepatic HBV-specific CD8(+) T cells and HBV-nonspecific inflammatory cells, the severity of liver fibrosis, and the development of HCC." | 1.38 | Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. ( Aiolfi, R; Chisari, FV; Di Lucia, P; Esposito, A; Fiocchi, A; Guidotti, LG; Iannacone, M; Mainetti, M; Mingozzi, F; Ruggeri, ZM; Sitia, G, 2012) |
| "Aspirin use was associated with reduced risk of developing HCC and of death due to CLD whereas nonaspirin NSAID use was only associated with reduced risk of death due to CLD." | 1.38 | Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. ( Freedman, ND; Graubard, BI; Gunja, MZ; Hollenbeck, AR; McGlynn, KA; Park, Y; Sahasrabuddhe, VV; Schwartz, LM; Trabert, B, 2012) |
| "The new human hepatoma cell line HBG BC2 possesses the capacity of being reversibly differentiated in vitro and of maintaining a relatively higher metabolic rate when in the differentiated state (3 weeks) as compared to HepG2 cells, and thus may allow the conduct of repeated toxicity testing on cells in culture." | 1.32 | A new hepatoma cell line for toxicity testing at repeated doses. ( Arrivet, E; Bichet, N; Fabre, N; Prenez, A; Roome, NO; Trancard, J; Vericat, JA, 2003) |
| " Combination therapy may produce synergic effects with better tumor inhibition as well as lower dosage or side affects." | 1.31 | [Effects of combination of octreotide and aspirin on proliferation of human hepatocellular carcinoma]. ( Tang, CW; Tang, LP; Wang, CH, 2002) |
| " The expression of ALDH3A1 in HepG2 cells showed typical time- and dose-response curves of induction after application of 3MC (1-5 days, 1." | 1.31 | Effects of 3-methylcholanthrene and aspirin co-administration on ALDH3A1 in HepG2 cells. ( Marselos, M; Pappas, P; Sotiropoulou, M, 2001) |
| " In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells." | 1.30 | Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. ( Cederbaum, AI; Chen, Q; Galleano, M, 1997) |
| "The role of influenza B in the pathogenesis of Reye's syndrome is unknown." | 1.27 | Protein synthesis by HepG2 cells infected with influenza B virus. ( Barnard, JA; Edwards, KM; Greene, HL; Snyder, PN; Werner, MJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.39) | 18.7374 |
| 1990's | 1 (0.88) | 18.2507 |
| 2000's | 7 (6.14) | 29.6817 |
| 2010's | 48 (42.11) | 24.3611 |
| 2020's | 53 (46.49) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 1 |
| Zhai, Y | 1 |
| Luo, W | 1 |
| Zhu, Z | 1 |
| Zhang, X | 4 |
| Xie, S | 1 |
| Hong, C | 1 |
| Wang, Y | 4 |
| Su, Y | 1 |
| Zhao, J | 2 |
| Wang, C | 1 |
| Zhang, L | 2 |
| Liu, L | 2 |
| Zheng, C | 1 |
| Nie, X | 1 |
| Shi, D | 1 |
| Chen, Y | 2 |
| Wei, G | 1 |
| Wang, J | 4 |
| Nischalke, HD | 1 |
| Klüners, A | 1 |
| Nattermann, J | 1 |
| Berg, T | 1 |
| Strassburg, CP | 1 |
| Lutz, P | 1 |
| Nierengarten, MB | 1 |
| Goh, MJ | 1 |
| Sinn, DH | 1 |
| Jang, H | 1 |
| Lee, YB | 2 |
| Moon, H | 2 |
| Chung, JW | 2 |
| Nam, JY | 1 |
| Cho, EJ | 2 |
| Lee, JH | 2 |
| Yu, SJ | 2 |
| Kim, YJ | 2 |
| Lee, J | 2 |
| Yoon, JH | 5 |
| Guidotti, LG | 3 |
| La Vecchia, C | 1 |
| Colombo, M | 1 |
| Yun, B | 1 |
| Ahn, SH | 1 |
| Kim, BK | 2 |
| Wang, M | 2 |
| Liu, C | 3 |
| Wang, W | 3 |
| Shi, J | 2 |
| Dang, S | 2 |
| Tan, JL | 1 |
| Sidhu-Brar, S | 1 |
| Woodman, R | 1 |
| Chinnaratha, MA | 1 |
| Koretz, RL | 1 |
| Wang, YF | 3 |
| Zhao, LN | 3 |
| Geng, Y | 3 |
| Yuan, HF | 4 |
| Hou, CY | 2 |
| Zhang, HH | 2 |
| Yang, G | 4 |
| Zhang, XD | 4 |
| Lai, SW | 3 |
| Stefanini, B | 1 |
| Tonnini, M | 1 |
| Marseglia, M | 1 |
| Tovoli, F | 1 |
| Ma, S | 1 |
| Qu, G | 1 |
| Sun, C | 1 |
| Liu, H | 2 |
| Jiang, Y | 2 |
| Li, N | 1 |
| Wu, B | 1 |
| Gao, J | 1 |
| Feng, L | 2 |
| Xie, P | 1 |
| Xia, W | 1 |
| Kim, NH | 1 |
| Lowe, S | 1 |
| Bentley, R | 1 |
| Zhu, Y | 2 |
| Zhou, Q | 2 |
| Sun, Y | 1 |
| Zeng, RW | 1 |
| Yong, JN | 1 |
| Tan, DJH | 1 |
| Fu, CE | 1 |
| Lim, WH | 1 |
| Xiao, J | 1 |
| Chan, KE | 1 |
| Tan, C | 1 |
| Goh, XL | 1 |
| Chee, D | 1 |
| Syn, N | 1 |
| Tan, EX | 1 |
| Muthiah, MD | 1 |
| Ng, CH | 1 |
| Tamaki, N | 1 |
| Lee, SW | 2 |
| Nguyen, MH | 2 |
| Loomba, R | 1 |
| Huang, DQ | 1 |
| Kraglund, F | 1 |
| Christensen, DH | 1 |
| Eiset, AH | 1 |
| Villadsen, GE | 1 |
| West, J | 1 |
| Jepsen, P | 1 |
| El Sadda, RR | 1 |
| Elshahawy, ZR | 1 |
| Saad, EA | 1 |
| Feng, JY | 2 |
| Zhao, M | 2 |
| Wei, XF | 1 |
| Wang, GW | 1 |
| Liao, KF | 2 |
| Goethe, EA | 1 |
| Heimberger, AB | 1 |
| Rao, G | 1 |
| Aktan, H | 1 |
| Ozdemir, AA | 1 |
| Karaoğullarindan, Ü | 1 |
| Wang, S | 2 |
| Zuo, L | 1 |
| Lin, Z | 1 |
| Yang, Z | 1 |
| Chen, R | 1 |
| Xu, Y | 1 |
| Lee, CH | 1 |
| Wu, JL | 1 |
| Luo, JY | 1 |
| Deng, XY | 1 |
| Jiang, ZB | 1 |
| Khajeh, E | 1 |
| Aminizadeh, E | 1 |
| Moghadam, AD | 1 |
| Ramouz, A | 1 |
| Klotz, R | 1 |
| Golriz, M | 1 |
| Merle, U | 1 |
| Springfeld, C | 1 |
| Chang, DH | 1 |
| Longerich, T | 1 |
| Büchler, MW | 1 |
| Mehrabi, A | 1 |
| Huang, R | 1 |
| Zhang, Z | 1 |
| Zhang, S | 2 |
| Wu, C | 1 |
| Hao, M | 1 |
| Li, Y | 1 |
| Du, ZQ | 1 |
| Zhao, JZ | 1 |
| Dong, J | 1 |
| Bi, JB | 1 |
| Ren, YF | 1 |
| Zhang, J | 2 |
| Khalid, B | 1 |
| Wu, Z | 1 |
| Lv, Y | 1 |
| Zhang, XF | 1 |
| Wu, RQ | 1 |
| Roehlen, N | 1 |
| Baumert, TF | 1 |
| Yu, Y | 2 |
| Ryan, PM | 1 |
| Dang, M | 1 |
| Clark, C | 1 |
| Kontogiannis, V | 1 |
| Rahmani, J | 1 |
| Varkaneh, HK | 1 |
| Salehisahlabadi, A | 1 |
| Day, AS | 1 |
| Zhang, Y | 1 |
| Liao, YH | 1 |
| Hsu, RJ | 1 |
| Wang, TH | 1 |
| Wu, CT | 1 |
| Huang, SY | 1 |
| Hsu, CY | 1 |
| Su, YC | 1 |
| Hsu, WL | 1 |
| Liu, DW | 1 |
| Shin, S | 1 |
| Lee, SH | 1 |
| Lee, M | 1 |
| Kim, JH | 1 |
| Lee, W | 1 |
| Lee, HW | 1 |
| Park, MS | 1 |
| Park, S | 1 |
| Kim, TS | 1 |
| Choi, DH | 1 |
| Simon, TG | 6 |
| Duberg, AS | 1 |
| Aleman, S | 1 |
| Chung, RT | 2 |
| Chan, AT | 5 |
| Ludvigsson, JF | 3 |
| Lee, TY | 2 |
| Hsu, YC | 2 |
| Tseng, HC | 2 |
| Lin, JT | 2 |
| Wu, MS | 2 |
| Wu, CY | 2 |
| Kuo, YH | 1 |
| Liao, R | 1 |
| Zhou, BY | 1 |
| Wu, ZJ | 1 |
| Carey, W | 1 |
| Romero-Marrero, C | 1 |
| Shi, T | 1 |
| Fujita, K | 1 |
| Gong, J | 1 |
| Nakahara, M | 1 |
| Iwama, H | 1 |
| Liu, S | 4 |
| Yoneyama, H | 1 |
| Morishita, A | 1 |
| Nomura, T | 1 |
| Tani, J | 1 |
| Takuma, K | 1 |
| Tadokoro, T | 1 |
| Himoto, T | 1 |
| Oura, K | 1 |
| Tsutsui, K | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Kusnik, A | 1 |
| Teufel, A | 1 |
| Liu, YW | 1 |
| Xu, HQ | 1 |
| Niu, JQ | 1 |
| Li, X | 2 |
| Klose, G | 1 |
| Casadei-Gardini, A | 1 |
| Rovesti, G | 1 |
| Dadduzio, V | 1 |
| Vivaldi, C | 1 |
| Lai, E | 1 |
| Lonardi, S | 1 |
| Fornaro, L | 1 |
| Pretta, A | 1 |
| Zagonel, V | 1 |
| Bernardini, L | 1 |
| Astara, G | 1 |
| D'Amico, FE | 1 |
| Masi, G | 1 |
| Rimini, M | 1 |
| Scartozzi, M | 1 |
| Cascinu, S | 1 |
| Chuang, TF | 1 |
| Chen, ST | 1 |
| Wei, JC | 1 |
| Liu, Y | 1 |
| Ren, T | 1 |
| Xu, X | 2 |
| Jin, J | 1 |
| Hui, VW | 1 |
| Yip, TC | 1 |
| Wong, VW | 1 |
| Tse, YK | 1 |
| Chan, HL | 1 |
| Lui, GC | 1 |
| Wong, GL | 1 |
| Singh, J | 1 |
| Wozniak, A | 1 |
| Cotler, SJ | 1 |
| Dhanarajan, A | 1 |
| Aldrich, D | 1 |
| Park, D | 1 |
| Kasia, C | 1 |
| Schmidt, B | 1 |
| Scaglione, S | 1 |
| Ricciotti, E | 1 |
| Wangensteen, KJ | 1 |
| FitzGerald, GA | 1 |
| Yuan, Y | 1 |
| Yun, HL | 1 |
| Choi, WM | 1 |
| Kim, HJ | 1 |
| Jo, AJ | 1 |
| Choi, SH | 1 |
| Han, S | 1 |
| Ko, MJ | 1 |
| Lim, YS | 1 |
| Danta, M | 1 |
| Tan, RZH | 1 |
| Lockart, I | 1 |
| Abdel Shaheed, C | 1 |
| Da Fonseca, LG | 1 |
| Forner, A | 1 |
| Sun, D | 1 |
| Dai, X | 1 |
| Zheng, X | 1 |
| Yan, J | 1 |
| Wei, R | 1 |
| Fu, X | 2 |
| Huang, M | 1 |
| Shen, A | 1 |
| Huang, X | 1 |
| Ding, J | 2 |
| Geng, M | 1 |
| Li, S | 1 |
| Dai, W | 1 |
| Mo, W | 1 |
| Li, J | 1 |
| Feng, J | 1 |
| Wu, L | 1 |
| Liu, T | 1 |
| Yu, Q | 1 |
| Xu, S | 1 |
| Lu, X | 1 |
| Zhang, Q | 1 |
| Chen, K | 1 |
| Xia, Y | 1 |
| Lu, J | 1 |
| Zhou, Y | 1 |
| Fan, X | 1 |
| Xu, L | 1 |
| Guo, C | 1 |
| Abdelmonsif, DA | 1 |
| Sultan, AS | 1 |
| El-Hadidy, WF | 1 |
| Abdallah, DM | 1 |
| Miao, R | 1 |
| Wang, Z | 1 |
| Qu, K | 1 |
| Chen, W | 1 |
| Huang, Z | 1 |
| Fang, W | 1 |
| Liu, W | 1 |
| Wang, L | 2 |
| Liu, B | 2 |
| Hwang, IC | 1 |
| Chang, J | 1 |
| Kim, K | 1 |
| Park, SM | 1 |
| Liu, YX | 1 |
| Sun, MM | 1 |
| Liu, BW | 1 |
| Bu, YN | 1 |
| Wang, TJ | 1 |
| Zhang, WY | 1 |
| Tseng, CH | 1 |
| Seewaldt, VL | 1 |
| Ma, Y | 1 |
| Chong, DQ | 1 |
| Giovannucci, EL | 1 |
| Fuchs, CS | 1 |
| Meyerhardt, JA | 1 |
| Corey, KE | 1 |
| Yu, SH | 1 |
| Fox, RK | 1 |
| Taddei, TH | 1 |
| Kaplan, DE | 1 |
| Chien, N | 1 |
| Yeo, YH | 1 |
| Skelin, M | 1 |
| Javor, E | 1 |
| Lucijanic, M | 1 |
| Barnard, ME | 1 |
| Young, SH | 1 |
| Chau, GY | 1 |
| Lee, IC | 1 |
| Yeh, YC | 1 |
| Chao, Y | 2 |
| Huo, TI | 2 |
| Su, CW | 2 |
| Lin, HC | 2 |
| Hou, MC | 1 |
| Lee, MH | 1 |
| Huang, YH | 2 |
| Fujiwara, N | 1 |
| Singal, AG | 1 |
| Hoshida, Y | 1 |
| Wang, T | 1 |
| Jin, T | 1 |
| Wu, Y | 1 |
| Xu, F | 1 |
| Wang, X | 1 |
| Ye, K | 1 |
| Zhang, W | 2 |
| Ye, L | 1 |
| Moeini, A | 1 |
| Torrecilla, S | 1 |
| Tovar, V | 1 |
| Montironi, C | 1 |
| Andreu-Oller, C | 1 |
| Peix, J | 1 |
| Higuera, M | 1 |
| Pfister, D | 1 |
| Ramadori, P | 1 |
| Pinyol, R | 1 |
| Solé, M | 1 |
| Heikenwälder, M | 1 |
| Friedman, SL | 1 |
| Sia, D | 1 |
| Llovet, JM | 1 |
| Orman, ES | 1 |
| Hayashi, PH | 1 |
| Singh, P | 1 |
| Singh, S | 2 |
| De Bruin, ML | 1 |
| Duijnhoven, RG | 1 |
| Li, G | 2 |
| Fang, H | 1 |
| Yan, B | 1 |
| Zhao, Y | 1 |
| Ma, X | 1 |
| Ye, X | 1 |
| Li, T | 1 |
| Dong, ZR | 1 |
| Guo, ZY | 1 |
| Wang, CH | 2 |
| Tang, ZY | 2 |
| Qu, SF | 1 |
| Chen, ZT | 1 |
| Li, XW | 1 |
| Zhi, XT | 1 |
| Kim, AK | 1 |
| Dziura, J | 1 |
| Strazzabosco, M | 1 |
| He, H | 1 |
| Lou, L | 1 |
| Ye, W | 1 |
| Lu, L | 2 |
| Sun, HC | 1 |
| Chai, ZT | 1 |
| Zhu, XD | 1 |
| Kong, LQ | 1 |
| Wang, WQ | 1 |
| Zhang, KZ | 1 |
| Zhang, YY | 1 |
| Zhang, QB | 1 |
| Ao, JY | 1 |
| Li, JQ | 1 |
| Wu, WZ | 1 |
| Sitia, G | 2 |
| Iannacone, M | 2 |
| Sahasrabuddhe, VV | 2 |
| Gunja, MZ | 2 |
| Graubard, BI | 2 |
| Trabert, B | 2 |
| Schwartz, LM | 2 |
| Park, Y | 2 |
| Hollenbeck, AR | 2 |
| Freedman, ND | 2 |
| McGlynn, KA | 2 |
| Singh, PP | 1 |
| Roberts, LR | 1 |
| Sanchez, W | 1 |
| Carrat, F | 1 |
| He, Z | 1 |
| Peng, Y | 1 |
| Duan, W | 1 |
| Tian, Y | 1 |
| Hu, T | 1 |
| Cai, Y | 1 |
| Feng, Y | 1 |
| Lu, M | 1 |
| Pei, Y | 1 |
| Chen, J | 1 |
| Qin, L | 1 |
| Zhu, W | 1 |
| Jia, H | 1 |
| Jiang, T | 1 |
| Duan, B | 1 |
| Lu, S | 1 |
| Gao, M | 1 |
| Kong, Q | 1 |
| Hua, H | 1 |
| Yin, Y | 1 |
| Luo, T | 1 |
| Hu, YN | 1 |
| Gu, SY | 1 |
| Zhang, ZZ | 1 |
| Lee, PC | 1 |
| Yeh, CM | 1 |
| Hu, YW | 1 |
| Chen, CC | 1 |
| Liu, CJ | 1 |
| Chen, TJ | 1 |
| Wu, JC | 1 |
| Kim, SO | 1 |
| Han, SY | 1 |
| Baek, YH | 1 |
| Han, JS | 1 |
| Kim, BG | 1 |
| Cho, JH | 1 |
| Nam, KJ | 1 |
| Raza, H | 1 |
| John, A | 1 |
| Benedict, S | 1 |
| Hossain, MA | 2 |
| Kim, DH | 2 |
| Jang, JY | 2 |
| Kang, YJ | 2 |
| Moon, JO | 2 |
| Chung, HY | 2 |
| Kim, GY | 2 |
| Choi, YH | 2 |
| Copple, BL | 2 |
| Kim, ND | 2 |
| Aiolfi, R | 1 |
| Di Lucia, P | 1 |
| Mainetti, M | 1 |
| Fiocchi, A | 1 |
| Mingozzi, F | 1 |
| Esposito, A | 1 |
| Ruggeri, ZM | 1 |
| Chisari, FV | 1 |
| Levy, IG | 1 |
| Pim, CP | 1 |
| Tang, CW | 1 |
| Tang, LP | 1 |
| Fabre, N | 1 |
| Arrivet, E | 1 |
| Trancard, J | 1 |
| Bichet, N | 1 |
| Roome, NO | 1 |
| Prenez, A | 1 |
| Vericat, JA | 1 |
| Horani, MH | 1 |
| Gobal, F | 1 |
| Haas, MJ | 1 |
| Wong, NC | 1 |
| Mooradian, AD | 1 |
| Grau, MV | 1 |
| Rees, JR | 1 |
| Baron, JA | 1 |
| Trujillo-Murillo, K | 1 |
| Rincón-Sánchez, AR | 1 |
| Martínez-Rodríguez, H | 1 |
| Bosques-Padilla, F | 1 |
| Ramos-Jiménez, J | 1 |
| Barrera-Saldaña, HA | 1 |
| Rojkind, M | 1 |
| Rivas-Estilla, AM | 1 |
| Mahmud, I | 1 |
| Miura, Y | 1 |
| Chen, Q | 1 |
| Galleano, M | 1 |
| Cederbaum, AI | 1 |
| Sotiropoulou, M | 1 |
| Pappas, P | 1 |
| Marselos, M | 1 |
| Abiru, S | 1 |
| Nakao, K | 1 |
| Ichikawa, T | 1 |
| Migita, K | 1 |
| Shigeno, M | 1 |
| Sakamoto, M | 1 |
| Ishikawa, H | 1 |
| Hamasaki, K | 1 |
| Nakata, K | 1 |
| Eguchi, K | 1 |
| Schmähl, D | 1 |
| Barnard, JA | 1 |
| Snyder, PN | 1 |
| Werner, MJ | 1 |
| Greene, HL | 1 |
| Edwards, KM | 1 |
| Hruban, Z | 1 |
| Swift, H | 1 |
| Slesers, A | 1 |
| Apps, MC | 1 |
| Cater, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 1st Generation EGFR-TKI Due to Acquisition of EGFR T790M[NCT03543683] | 330 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Epidermal Growth Factor Receptor(EGFR)-Mutation[NCT04184921] | 350 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor（EGFR-TKI） Osimertinib[NCT03532698] | 100 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for aspirin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Topics: Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2022 |
Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Risk Fa | 2022 |
Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Gastrointestinal Hemorrhage; Hepatitis, Viral, Human; Humans; In | 2023 |
Aspirin use is associated with reduced risk for hepatocellular carcinoma.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2022 |
Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Incidence; Liver Neoplasms; Proportional Hazards Models | 2023 |
Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Topics: Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2023 |
Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2023 |
The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Prospectiv | 2023 |
Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Carcinoma, Hepat | 2020 |
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
Topics: Alcohol Drinking; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; Diabetes Mellitus, Type 2; Di | 2020 |
[Effect of aspirin on hepatocellular carcinoma and its related mechanism].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Gastrointestinal Neopla | 2020 |
Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Treatment Outcom | 2021 |
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms | 2020 |
Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Hepatit | 2022 |
Aspirin in Hepatocellular Carcinoma.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies | 2021 |
Chemopreventive strategies in hepatocellular carcinoma.
Topics: Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Hepatitis; Humans; Hydroxymet | 2014 |
Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Evidence-Based Medicine | 2014 |
Chemoprevention in gastrointestinal cancers: current status.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Clinical Trials as Topi | 2006 |
96 other studies available for aspirin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Car | 2016 |
Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line | 2017 |
Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link?
Topics: Aspirin; Blood Platelets; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Platelet Aggregation I | 2021 |
Aspirin decreases the risk of hepatocellular cancer in at-risk patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2022 |
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
Topics: Adult; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence | 2022 |
Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B virus; Humans; Liver Cirrhosis; Liver Neoplasms; Ris | 2022 |
Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
Topics: Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2022 |
Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Glycolysis; Histone Acetyltransfera | 2023 |
Letter to the editor: Aspirin use and the risk of hepatocellular carcinoma.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2022 |
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinom | 2022 |
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials.
Topics: Aspirin; Carcinoma, Hepatocellular; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2023 |
Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C.
Topics: Animals; Ascorbic Acid; Aspirin; Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Ra | 2023 |
Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription.
Topics: Amino Acid Transport System y+; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; H | 2023 |
Aspirin and immunotherapy: a Faustian bargain?
Topics: Aspirin; Carcinoma, Hepatocellular; Fibrinogen; Humans; Immunotherapy; Liver Neoplasms | 2023 |
Effect of aspirin use on survival in patients with hepatocellular carcinoma.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Risk Factors; Survival Rate | 2023 |
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neo | 2023 |
Letter: Causal relationship between aspirin and the risk of hepatocellular carcinoma remains unproven.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2023 |
Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatectomy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2023 |
Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression.
Topics: Animals; Aspirin; B7-H1 Antigen; Carcinoma, Hepatocellular; Diethylnitrosamine; Inflammation; Liver | 2023 |
Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up | 2019 |
Uncovering the mechanism of action of aspirin in HCC chemoprevention.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans; Liver Neoplasms | 2019 |
Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase Inhibitors; Femal | 2020 |
Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis.
Topics: Aged; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Incidence; Liver Cirrhosis, Alcoholic; Liv | 2020 |
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Gastroin | 2020 |
Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection.
Topics: Aged; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis C, Chronic; Hu | 2020 |
The risk of hepatocellular carcinoma and aspirin use.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Risk Factors | 2020 |
Association between Aspirin and Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2020 |
Association between Aspirin and Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2020 |
Association between Aspirin and Hepatocellular Carcinoma. Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2020 |
Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis.
Topics: Animals; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB R | 2020 |
[Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Diseases; | 2020 |
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
Topics: Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compo | 2021 |
Daily Aspirin Therapy Reduces the Risk of Hepatocellular Carcinoma on Chronic HCV Hepatitis.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Liver Neop | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combinatio | 2021 |
Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma.
Topics: Aspirin; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hum | 2022 |
Aspirin modulates 2-hydroxyisobutyrylation of ENO1K281 to attenuate the glycolysis and proliferation of hepatoma cells.
Topics: Antineoplastic Agents; Aspirin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2021 |
Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study.
Topics: Aspirin; Carcinoma, Hepatocellular; Case-Control Studies; Hepatitis B, Chronic; Humans; Hydroxymethy | 2021 |
Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma - ready for their use? Authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans | 2021 |
Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma-ready for their use?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Humans | 2021 |
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agen | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Aspirin; beta | 2018 |
Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Carcinoma, Hepatocel | 2018 |
Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Aspirin; Autophagy; Beclin-1; C | 2018 |
Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinogenesis; Carcinom | 2018 |
Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2019 |
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Topics: Aged; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Diabetes Mellitus, Typ | 2018 |
Aspirin and Chemoprevention-Have We Arrived?
Topics: Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Colorectal Neoplasms; Humans; Liver Neoplasms | 2018 |
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Humans; | 2018 |
Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; | 2019 |
Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms | 2019 |
Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Risk Assessment; Risk Factors | 2019 |
Aspirin Use and the Risk of Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2019 |
Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin-In Reply.
Topics: Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Risk Assessment; Risk Factors | 2019 |
Aspirin Use and the Risk of Cancer-In Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2019 |
Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Female; Hepatectomy; | 2020 |
Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms | 2019 |
Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Contro | 2019 |
Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Liver D | 2013 |
Re: nonsteroidal antiinflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Liver D | 2013 |
Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Liver D | 2013 |
Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspiri | 2013 |
Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway.
Topics: Animals; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplas | 2013 |
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Liver D | 2013 |
Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Blo | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferatio | 2013 |
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Aspirin; Blood Platelets; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proli | 2013 |
Response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Humans; Liver D | 2013 |
Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway.
Topics: Acetyl-CoA Carboxylase; Acyl-CoA Dehydrogenase; AMP-Activated Protein Kinases; Aspirin; Carcinoma, H | 2015 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyc | 2015 |
Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Cathet | 2015 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2016 |
[The Experiment Study and Mechanism of Aspirin Enhances Cellular Sensitivity of Hepatocellular Carcinoma Cell Line to Arsenic Trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2016 |
Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Clopidogrel; Disease-Free Survival; Female; Gastroi | 2016 |
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; | 2011 |
Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Biomarkers; Carcinoma, Hepa | 2011 |
Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cel | 2012 |
Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspirin; C | 2012 |
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
Topics: Analysis of Variance; Animals; Aspirin; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Clopi | 2012 |
An aspirin a day: the allure (and distraction) of chemoprevention.
Topics: Alcohol Drinking; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin | 2012 |
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; | 2012 |
[Effects of combination of octreotide and aspirin on proliferation of human hepatocellular carcinoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Hepatocellular; Cell Di | 2002 |
A new hepatoma cell line for toxicity testing at repeated doses.
Topics: Acetaminophen; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Dru | 2003 |
Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2.
Topics: Apolipoprotein A-I; Arachidonic Acid; Aspirin; Blotting, Northern; Blotting, Western; Carcinoma, Hep | 2004 |
Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.
Topics: Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase 2; Genotype; Hepacivirus; Human | 2008 |
Effects of stimulators and inhibitors on arachidonic acid metabolism in hepatoma.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Butylated Hydroxytoluene; Carcinoma, Hepatoce | 1981 |
Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1.
Topics: alpha-Tocopherol; Antioxidants; Apoptosis; Ascorbic Acid; Aspirin; Carcinoma, Hepatocellular; Cell S | 1997 |
Effects of 3-methylcholanthrene and aspirin co-administration on ALDH3A1 in HepG2 cells.
Topics: Aldehyde Dehydrogenase; Aspirin; Carcinoma, Hepatocellular; Cell Survival; Drug Interactions; Glutat | 2001 |
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase 2; Cyclo | 2002 |
[Studies on the influence of anticoagulants on metastase formation of autochthonic hepatomas in the rat (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Carcinoma, Hepatocellular; Coumarins; Diethylnitrosamine; Female; | 1975 |
Protein synthesis by HepG2 cells infected with influenza B virus.
Topics: Aspirin; Blood Proteins; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Humans; Influenza B | 1988 |
Ultrastructural alterations of hepatic microbodies.
Topics: Anilides; Animals; Aspirin; Benzoates; Body Weight; Carcinoma, Hepatocellular; Kidney; Liver; Liver | 1966 |
Production of histamine-like and prostaglandin-like substances from serum incubated with rat, dog, mouse or human tumours.
Topics: Acetates; Animals; Aspirin; Carcinoma, Hepatocellular; Complement System Proteins; Dogs; Histamine; | 1973 |